| Friday 10 September, 2010 |
GöteborgBIO
Medicinaregatan 8A
SE- 413 46 Göteborg
Sweden
Phone: +46 (0)31 - 61 24 02
Fax: +46 (0)31 - 41 97 00
Arterion
, which produces artificial blood vessels developed from bacterial cellulose, received the MedTech Investment Day Award during the MedTech Investment Day event on February 11.Arterion develops customised biomaterials based on bacterial cellulose and has its sights set on using artificial blood vessels to solve a problem that afflicts three million vascular disease patients a year — poor-quality spare parts.
“Arterion satisfies a large, hitherto unfulfilled need with a simple yet elegant and innovative idea. It´s a solution with many potential applications, and Arterion´s team has succeeded in focusing on one specific area. We met an enthusiastic and highly expert team with their feet planted firmly on the ground."
That was the jury´s statement explaining why Arterion received the MedTech Investment Day Award, whose purpose is to highlight examples of future medtech developments and to underscore that medtech is an industry with immense growth potential.
The jury consisted of Gisela Sitbon, Deputy Director Region Mitt at Innovationsbron, Johanna Adami, section manager at Vinnova, Tommy Hedberg, President Atos Medical and Jonas Hansson of risk capital company HealthCap. The award consists of a cheque for 50,000 kronor and one year´s membership in Swecare.
February 11, 2010 marked the second time the MedTech Investment Day was held. About 150 people participated in the event at KistaScienceTower, at which 30 or so investors from Sweden, the USA, India and China met with 22 selected innovative medtech companies.
Contact persons:
Karl Richard Nilsson, President, Arterion: +46 705-78 56 77, karl@arterion.se
Mia Engman, publicity manager, Swedish Medtech: +46 76-538 46 05, mia.engman@swedishmedtech.se
